188397-74-2

Upstream product

• 117283-10-0 N-(1-Cyano-2,2,2-trifluoro-1-trifluoromethyl-ethyl)-4-fluoro-benzamide 
• 49854-61-7 4-fluoro-N-<2,2,2-trifluoro-1-(trifluoromethyl)ethylidene>benzamide 
• 151-50-8 potassium cyanide 

Downstream Products

• 139982-66-4 2-(4-Fluoro-phenyl)-3-methyl-5,5-bis-trifluoromethyl-3,5-dihydro-imidazol-4-one 
• 33469-33-9 2-(4-fluorophenyl)-1-methyl-4-(trifluoromethyl)-4H-imidazol 
• 188397-81-1 4-Fluoro-N-[2-(4-fluoro-phenyl)-3-methyl-5-trifluoromethyl-3H-imidazol-4-yl]-benzamide 
• 188397-79-7 (4-Fluoro-phenyl)-[2-(4-fluoro-phenyl)-3-methyl-5-trifluoromethyl-3H-imidazol-4-yl]-methanone 
• 188397-75-3 2-(4-Fluoro-phenyl)-3-methyl-5,5-bis-trifluoromethyl-4,5-dihydro-3H-imidazol-4-ol 

Relevant academic research and scientific papers

Asymmetric synthesis and absolute stereochemistry of 4,4-bis(trifluoromethyl)imidazoline based ACAT inhibitors

An asymmetric synthesis of 1, a potent orally active ACAT inhibitor, is reported. The absolute configuration of 1 has been determined by exciton CD spectra and X-ray crystal structure analysis.

An Unusual Trifluoromethyl Elimination Reaction from the 4,4-Bis(trifluoromethyl)-5-hydroxyimidazoline Ring System

A facile detrifluoromethylation was observed when 4,4-bis(trifluoromethyl)-5-hydroxyimidazoline 5 was treated with a variety of bases to afford the biologically interesting 4-(trifluoromethyl)- imidazole analogs (9 and 10). A unique mechanism was proposed for this transformation, supported by isolating and trapping the hypothesized intermediates. Heating of 5 with Et4NCN in DMSO provided 19, which was clearly derived from the proposed intermediate 17. Finally, imidazole 9 was converted into the N-[2-phenyl-4-(trifluoromethyl)-]1H-imidazol-5-yl]-N-methylbenzamide analogs, which were potential acyl CoA:cholesterol acyltransferase (ACAT) inhibitors.